Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.
Clot PF, Farenc C, Suratt BT, Krahnke T, Tardat A, Florian P, Pomponio R, Patel N, Wiekowski M, Lin Y, Terrier B, Staudinger H. Clot PF, et al. Among authors: tardat a. Respir Res. 2024 Feb 28;25(1):107. doi: 10.1186/s12931-024-02670-z. Respir Res. 2024. PMID: 38419035 Free PMC article. Clinical Trial.
Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial.
Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Bergougnan L, et al. Among authors: tardat a. Br J Clin Pharmacol. 2021 May;87(5):2303-2320. doi: 10.1111/bcp.14632. Epub 2020 Nov 26. Br J Clin Pharmacol. 2021. PMID: 33125753 Free PMC article. Clinical Trial.
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.
Bergougnan L, Armani S, Golor G, Tardat A, Vitse O, Hurbin F, Scemama M, Poitiers F, Radzik D, Gaudin C, Hovsepian L, Muslin AJ, Kirkesseli S, Deutsch P, Parkar AA. Bergougnan L, et al. Among authors: tardat a. Br J Clin Pharmacol. 2021 Feb;87(2):598-611. doi: 10.1111/bcp.14422. Epub 2020 Jul 8. Br J Clin Pharmacol. 2021. PMID: 32520410 Free PMC article. Clinical Trial.